Feng, Mingye
Marjon, Kristopher D.
Zhu, Fangfang
Weissman-Tsukamoto, Rachel
Levett, Aaron
Sullivan, Katie
Kao, Kevin S.
Markovic, Maxim
Bump, Paul A.
Jackson, Hannah M.
Choi, Timothy S. http://orcid.org/0000-0002-3540-0368
Chen, Jing
Banuelos, Allison M.
Liu, Jie
Gip, Phung
Cheng, Lei
Wang, Denong
Weissman, Irving L. http://orcid.org/0000-0002-9077-7467
Funding for this research was provided by:
Damon Runyon Cancer Research Foundation (DFS-22-16)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (K99CA201075/R00CA201075, R01CA086017, P01CA139490)
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (T32DK098132)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R56AI118464)
Article History
Received: 24 December 2017
Accepted: 19 June 2018
First Online: 10 August 2018
Competing interests
: M.F. declares patent applications pertaining to stimulating TLR/BTK signaling to promote CRT in macrophages assigned to the Stanford University and equity and/or consulting with Forty Seven, Inc. I.L.W. is a cofounder and member of the board of directors for Forty Seven, Inc., a company that is developing therapies involving the CD47-SIRPĪ± axis. P.G. and J.L. are currently employees of Forty Seven, Inc. The remaining authors declare no competing interests.